The precise pathogenic roles of mutated KRAS and NRAS in AML have not yet been fully elucidated, primarily because RAS mutations typically occur as secondary events that contribute to the clonal evolution of AML. This evidence concerns the gene KRAS and acute myeloid leukemia.